Charles River Announces Agreement to Supply Pfizer’s Genetically Modified Research Models
March 03 2011 - 8:30AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has entered into a marketing and distribution
agreement with Pfizer Inc. (NYSE: PFE), the world’s leading
biopharmaceutical company, to provide certain Pfizer-developed
genetically modified research models to the global biomedical
research community. Under this agreement, Charles River will supply
a number of pre-competitive, transgenic research models developed
by Pfizer across a broad range of therapeutic areas, including
neuroscience, diabetes and cardiovascular disease.
“Charles River is extremely pleased to partner with Pfizer to
further expand our growing portfolio of genetically modified
research models that we can make available to our global client
base,” said Dr. Iva Morse, Corporate Vice President, Global
Research Model Services at Charles River. “The use of genetically
modified research models continues to emerge as an important tool
to allow scientists in their research to target specific disease
states and genetic markers. We appreciate that Pfizer has selected
Charles River to bring their unique models to market, and the
biomedical research community will undoubtedly benefit from access
to Pfizer’s world-class transgenic model portfolio.”
Rick Connell, Vice President and Worldwide Head of External
Research Solutions Center of Excellence at Pfizer, added, “This
agreement with Charles River aligns with Pfizer’s strategy to
externalize our pre-competitive tools and assets to a broader
community of scientists outside of Pfizer’s walls. We collectively
share an interest in seeing science advance to enable the continued
development of innovative medicines for patients. Charles River is
a leader in providing products and services to the biomedical
research community, so we expect that our genetically modified
models will be delivered to their clients with the highest
standards of quality and care for which they are globally
recognized.”
Caution Concerning Forward-Looking
Statements
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “anticipate,” “believe,” “expect,” “will,” “may,”
“estimate,” “plan,” “outlook,” and “project” and other similar
expressions that predict or indicate future events or trends or
that are not statements of historical matters. These statements
also include statements regarding the future benefits and
opportunities to be derived from Pfizer’s transgenic or genetically
modified models, and the acceptance and adoption of these models as
drug discovery and development tools. Forward-looking statements
are based on Charles River’s current expectations and beliefs, and
involve a number of risks and uncertainties that are difficult to
predict and that could cause actual results to differ materially
from those stated or implied by the forward-looking statements.
Those risks and uncertainties include risks, uncertainties, and
other matters found in the Risk Factors detailed in Charles River's
Annual Report on Form 10-K as filed on February 23, 2011, as well
as other filings we make with the Securities and Exchange
Commission. Because forward-looking statements involve risks and
uncertainties, actual results and events may differ materially from
results and events currently expected by Charles River, and Charles
River assumes no obligation and expressly disclaims any duty to
update information contained in this news release except as
required by law.
About Charles River
Accelerating Drug Development. Exactly. Charles River provides
essential products and services to help pharmaceutical and
biotechnology companies, government agencies and leading academic
institutions around the globe accelerate their research and drug
development efforts. Our approximately 7,500 employees worldwide
are focused on providing clients with exactly what they need to
improve and expedite the discovery, development through
first-in-human evaluation, and safe manufacture of new therapies
for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From May 2024 to Jun 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jun 2023 to Jun 2024